Drug Search Results
More Filters [+]


Alternative Names: IDRX-42, IDRX 42, IDRX42
Latest Update: 2024-06-03
Latest Update Note: News Article

Product Description

IDRX-42, an orally administered small molecule tyrosine kinase inhibitor, is a drug candidate from IDRx for the treatment of Metastatic and/or Unresectable Gastrointestinal Stromal Tumors. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05489237?term=IDRX-42&draw=2&rank=1)

Mechanisms of Action: TK Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: IDRX,Inc./Qiu Yisi (Shanghai) Medical Information Consulting Co., Ltd./Aptuit (Verona) Srl/Aptuit (Verona) Srl
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for IDRX-42

Countries in Clinic: Belgium, Germany, Spain, United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Digestive System Cancer|Gastrointestinal Cancer|Gastrointestinal Stromal Tumors|Intestinal Diseases



Trial Status


Primary Completion Date

Probability of Success

StrateGIST 1]



Intestinal Diseases|Gastrointestinal Stromal Tumors|Gastrointestinal Cancer|Digestive System Cancer


Recent News Events